Total amount raised
$12.5 Million
Latest funding date
10/1/2020
Location
Loyal has successfully raised funds from 20 investors, including Collaborative Fund and Valor Equity Partners, participating in a Series B funding round. The company is focused on developing medicines to extend the lifespan and improve the quality of life for dogs.
Keep reading to explore the intricacies of Loyal's fundraising journey and the investors backing this innovative biotechnology platform.
What Is Loyal?
Loyal, founded in 2019 by Celine Halioua, is a biotechnology company based in San Francisco, California. The company focuses on developing medicines to extend the lifespan and improve the quality of life for dogs.
Operating in the biotechnology, pet, and veterinary industries, Loyal employs between 101-250 people. The company aims to slow the aging process in dogs, thereby delaying or preventing age-related diseases such as cancer and dementia.
How Much Funding Has Loyal Raised?
- Seed Round
- Amount Raised: $11M
- Date: January 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's research and development efforts in biotechnology for extending the lifespan of dogs.
- Venture Round
- Amount Raised: Not publicly disclosed
- Date: July 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop and validate their initial research findings.
- Series A
- Amount Raised: $27M
- Date: September 2021
- Lead Investors: Khosla Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand their research team and accelerate the development of their biotechnology solutions.
- Series A
- Amount Raised: $20M
- Date: April 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue their research and prepare for clinical trials.
- Series B
- Amount Raised: $45M
- Date: March 2024
- Lead Investors: Bain Capital Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund large-scale clinical trials and advance their drug development pipeline.
- Debt Financing
- Amount Raised: $12M
- Date: March 2024
- Lead Investors: Bridge Bank
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To provide additional working capital for ongoing projects.
- Series B-2
- Amount Raised: $22M
- Date: February 2025
- Lead Investors: Collaborative Fund, Valor Equity Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance clinical programs and prepare for potential commercialization of their longevity-focused veterinary pharmaceuticals.
Total Amount Raised: $137M
Current Valuation: Not publicly disclosed
Key Investors
- Collaborative Fund
- Details: Collaborative Fund is a venture capital firm that invests in companies focused on sustainability, health, and wellness.
- Investment Focus Areas: Sustainability, health, wellness
- Notable Investments: Not specified
- Valor Equity Partners
- Details: Valor Equity Partners is a private equity firm that invests in high-growth companies across various sectors.
- Investment Focus Areas: High-growth companies across various sectors
- Notable Investments: Not specified
- Bridge Bank
- Details: Bridge Bank is a division of Western Alliance Bank that provides financial services to small and mid-sized businesses.
- Investment Focus Areas: Financial services for small and mid-sized businesses
- Notable Investments: Not specified
- Bain Capital Ventures
- Details: Bain Capital Ventures is a venture capital firm that invests in early to growth-stage companies across multiple industries.
- Investment Focus Areas: Early to growth-stage companies across multiple industries
- Notable Investments: Not specified
- Khosla Ventures
- Details: Khosla Ventures is a venture capital firm that focuses on early-stage investments in technology and healthcare.
- Investment Focus Areas: Technology, healthcare
- Notable Investments: Not specified
What's Next for Loyal?
Loyal stands at the cusp of a transformative era in veterinary medicine, with the potential to revolutionize the longevity and health of dogs. The company's recent FDA RXE acceptance for LOY-002 and substantial funding indicate a promising future. As they advance clinical trials and prepare for commercialization, the opportunities for growth are immense.
Future fundraising efforts will likely focus on supporting these large-scale clinical trials and navigating the regulatory landscape. However, challenges such as proving drug efficacy and safety, and facing competition in the veterinary sector, remain. Loyal's journey is poised to be a significant chapter in the evolution of pet health.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Loyal and gather other critical business insights.
Sign up for free to start exploring the wealth of information available at your fingertips and gain a competitive edge in your sales efforts.
